Literature DB >> 17981532

Structure and function of the papillomavirus E6 protein and its interacting proteins.

Yuqi Liu1, James D Baleja.   

Abstract

Infection by high risk papillomavirus causes various forms of anogenital cancer including squamous cell carcinoma of the cervix. A primary step in the carcinogenesis includes formation of a complex of viral E6 protein and a human E3 ubiquitin ligase. This complex is competent to cause degradation and inactivation of several target proteins including human tumor suppressors which contributes to hyperproliferation of infected cells. Great insight on the mechanism by which E6 binds target proteins has recently been provided by determination of structures of interacting peptides and a E6 domain. These data have also provided a basis for the discovery of small molecules that can inhibit E6. However, there is still a need to further solve the structures of additional interacting complexes to identify the structural relationship that exists between proteins that simultaneously bind E6, such as E6AP and p53 or E6AP and PDZ domain-containing proteins, and to provide a clear picture of the interface between E6 and its ubiquitin ligase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17981532     DOI: 10.2741/2664

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  17 in total

1.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

Review 2.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

3.  Peptide-Protein Binding Investigated by Far-IR Spectroscopy and Molecular Dynamics Simulations.

Authors:  Yoann Cote; Yves Nominé; Juan Ramirez; Petra Hellwig; Roland H Stote
Journal:  Biophys J       Date:  2017-06-20       Impact factor: 4.033

4.  Biophysical characterization of the complex between human papillomavirus E6 protein and synapse-associated protein 97.

Authors:  Celestine N Chi; Anders Bach; Åke Engström; Kristian Strømgaard; Patrik Lundström; Neil Ferguson; Per Jemth
Journal:  J Biol Chem       Date:  2010-11-27       Impact factor: 5.157

5.  Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.

Authors:  Hongbo Wang; Pingli Mo; Shumei Ren; Chunhong Yan
Journal:  J Biol Chem       Date:  2010-02-18       Impact factor: 5.157

6.  The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis.

Authors:  Kim-Tat Teoh; Yu-Lam Siu; Wing-Lim Chan; Marc A Schlüter; Chia-Jen Liu; J S Malik Peiris; Roberto Bruzzone; Benjamin Margolis; Béatrice Nal
Journal:  Mol Biol Cell       Date:  2010-09-22       Impact factor: 4.138

8.  E6 proteins from diverse papillomaviruses self-associate both in vitro and in vivo.

Authors:  Katia Zanier; Christine Ruhlmann; Frederic Melin; Murielle Masson; Abdellahi Ould M'hamed Ould Sidi; Xavier Bernard; Benoit Fischer; Laurent Brino; Tutik Ristriani; Vladimir Rybin; Mireille Baltzinger; Scott Vande Pol; Petra Hellwig; Patrick Schultz; Gilles Travé
Journal:  J Mol Biol       Date:  2009-11-13       Impact factor: 5.469

9.  Determinants of stability for the E6 protein of papillomavirus type 16.

Authors:  Yuqi Liu; Jonathan J Cherry; Joseph V Dineen; Elliot J Androphy; James D Baleja
Journal:  J Mol Biol       Date:  2009-03-06       Impact factor: 5.469

Review 10.  Oncogenic activities of human papillomaviruses.

Authors:  Margaret E McLaughlin-Drubin; Karl Münger
Journal:  Virus Res       Date:  2009-06-18       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.